Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
ID: 356879Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," aimed at supporting pilot projects that explore the roles of understudied proteins linked to rare diseases. The objective is to generate preliminary data and tools related to these proteins, which are associated with rare diseases affecting fewer than 200,000 individuals in the U.S., thereby facilitating innovative research that could lead to new drug targets and treatments. Eligible applicants include a wide range of institutions, including educational and nonprofit organizations, government entities, and small businesses, with funding available up to $100,000 for projects that can be completed within one year. Interested parties can find more information and apply by contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by November 16, 2027.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for pilot projects aimed at studying understudied proteins linked to rare diseases. This funding opportunity, titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," is part of the R03 Small Grant Program and allows for projects that can be completed in one year with a budget of up to $100,000 in direct costs. The goal is to generate preliminary data on eligible understudied proteins, which are proteins with limited biological characterization that have known associations with rare diseases affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various educational and nonprofit institutions, government entities, and small businesses. The funding mechanism aims to facilitate innovative research that identifies new drug targets and catalyzes further studies in translational science, directly contributing to the development of treatments for the estimated 10,000 rare diseases. Applications must provide evidence linking the proposed understudied protein to a rare disease and are encouraged to employ non-animal methodologies. The initiative reflects NIH's commitment to enhancing biomedical research that addresses critical gaps in understanding rare conditions related to the human proteome.
    Similar Opportunities
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute of Neurological Disorders and Stroke (NINDS), has announced a funding opportunity titled "Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access" (X01), aimed at facilitating research in gene-based therapies for ultra-rare neurological disorders affecting fewer than 6,000 individuals in the U.S. This initiative provides investigators with access to contract research organizations (CROs) and subject matter experts to assist in planning, manufacturing, and nonclinical therapeutic development, specifically for the preparation of Investigational New Drug (IND) applications without involving clinical trials. The program emphasizes collaboration and strategic planning to address the unmet medical needs of patients with ultra-rare diseases, encouraging multidisciplinary project teams to outline development plans and regulatory considerations. Interested applicants must submit their proposals by January 24, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. Additional information can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-028.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which supports small clinical trials focused on basic experimental studies involving human participants. This funding opportunity aims to enhance understanding of fundamental phenomena without immediate application towards products or processes, aligning with the NICHD's mission in human development, behavior, and health. Grants are available for up to $50,000 in direct costs per year, with a maximum project duration of two years, and applications must be submitted by January 7, 2025. Interested applicants can find more information and application details at the NIH website or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for R34 Clinical Trial Pilot Studies aimed at supporting research that informs the planning of Phase II-IV clinical trials focused on heart, lung, blood, and sleep disorders. Applicants are required to demonstrate that their proposed studies are essential for the design of future trials and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote diversity within research teams. This initiative is critical for advancing clinical practice and understanding in these vital health areas, with awards of up to $450,000 available over three years. Interested applicants should submit their proposals by January 7, 2027, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.